Earlier this year The New York Times highlighted an unexpected but serious risk for the American consumer when a doctor or chemist prescribes or dispenses generic equivalent drugs, rather than the original patented brand. Who does one sue?
This is potentially of concern to South Africans, as generic equivalent medicines are widely used here, where approval and licensing procedures closely follow American precedents. The issue is graphically demonstrated by two case studies quoted in The New York Times.
While every reasonable effort is taken to ensure the accuracy and soundness of the contents of this publication, neither the authors nor the publishers of this website bear any responsibility for the consequences of any actions based on the information contained therein.